Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clervonafusp, an antibody targeting SLC29A2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zelminemab, an antibody targeting ADCYAP1R1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tesnatilimab, an antibody targeting KLRK1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Telazorlimab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ragifilimab, an antibody targeting TNFRSF18.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Praluzatamab, an antibody targeting ALCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pimurutamab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pacmilimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Miptenalimab, an antibody targeting LAG3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ivuxolimab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ezabenlimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bepranemab, an antibody targeting Tau.